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Abstract
Background: Lupus nephritis is associated with increased risk of end-stage renal disease (ESRD) and all-cause
mortality. We evaluated the clinical features and outcomes of patients with early and delayed lupus nephritis.
Methods: The medical records of 171 patients who met the 1997 revised classification criteria for systemic lupus
erythematosus (SLE) with pathologic confirmation of lupus nephritis were reviewed. Early lupus nephritis was
defined when lupus nephritis was histopathologically confirmed as the first clinical manifestation of SLE, whereas
delayed lupus nephritis was defined as lupus nephritis that was identified after the diagnosis of SLE. Clinical and
laboratory data, as well as kidney histopathology and medication usage were investigated. Kaplan-Meier and Cox-
proportional hazard analysis was performed to compare the outcomes of early and delayed lupus nephritis and
evaluate factors associated with ESRD and all-cause mortality.
Results: Patients with early lupus nephritis had higher disease activity (median non-renal SLE disease activity index-
2000, 6.0 vs. 4.0; p < 0.001) and more frequent skin rash, oral ulcer and serositis; however, the proportion of patients
with higher renal chronicity index was greater in the delayed lupus nephritis group (p = 0.007). Nevertheless, no
difference was found regarding ESRD and all-cause mortality between the groups. In Cox-proportional hazard
analysis, C-reactive protein level, creatinine level and chronicity index were factors associated with ESRD, while age
and haemoglobin level were associated with all-cause mortality.
Conclusions: In conclusion, clinical outcomes of early and delayed lupus nephritis are not significantly different.
Rigorous adherence to current treatment recommendations is essential for the treatment of lupus nephritis.
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Background
Systemic lupus erythematosus (SLE) is an idiopathic in-
flammatory disease characterized by multiple organ in-
jury as a result of autoantibody formation [1]. Lupus
nephritis is one of the most serious systemic
complication of SLE that affects up to 60–70% of pa-
tients with SLE during their lifetime [2]. Lupus nephritis
is classified into 6 different subtypes based on the patho-
logic findings, with class III and class IV (proliferative)
lupus nephritis being the most aggressive form [3]. The
treatment of proliferative lupus nephritis consists of in-
duction therapy, followed by maintenance therapy to
achieve remission [4]. However, the prognosis of patients
with lupus nephritis remains unfavourable even when
aggressive treatment strategies are implemented, mainly
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because of a significantly increased risk of end-stage
renal disease (ESRD) and all-cause mortality [5]. Accord-
ingly, the treatment guidelines for SLE recommend pru-
dent monitoring of patients for the development of
lupus nephritis [6]. In general, lupus nephritis primarily
occurs at the time of or within the first year of SLE diag-
nosis [7]. On the contrary, the frequency of lupus neph-
ritis occurrence gradually decreases with time; the onset
of lupus nephritis is reported to be uncommon after
5 years from SLE diagnosis [8].
Most patients with SLE are treated based on the organ
involved, and immunosuppressive agents, such as gluco-
corticoids and hydroxychloroquine, are the most widely
used drugs for the management of SLE [9]. A consider-
able number of patients who had been diagnosed with
SLE before lupus nephritis (delayed lupus nephritis),
may have been exposed to glucocorticoids and/or im-
munosuppressive drugs, while most patients diagnosed
with lupus nephritis as the first complication of SLE
(early lupus nephritis) may be glucocorticoid and/or im-
munosuppressive drug-naive. Therefore, it is theoretic-
ally assumed that the clinical features at the time of
kidney biopsy and the prognosis may differ between
early and delayed lupus nephritis proportionally to the
interval between the diagnosis of SLE and lupus neph-
ritis; however, the data from the literature regarding this
subject are scarce [10]. Therefore, the objectives of this
study were 1) to compare the clinical features of early
and delayed lupus nephritis at the time of kidney biopsy
and its prognosis and 2) to investigate factors associated




The records of patients diagnosed with lupus nephritis
by kidney biopsy between January 2006 and July 2018
were retrospectively reviewed. The following patients
were included: i) patients with histological findings
compatible with 2003 International Society of Nephrol-
ogy/ Renal Pathology Society (ISN/RPS) classification
criteria for lupus nephritis [3]; ii) patients who met the
1997 revised American College of Rheumatology (ACR)
classification criteria for SLE [11, 12]; iii) patients who
were not diagnosed with lupus nephritis prior to patho-
logical confirmation. In case of patients with repeated
histopathological results, the first result was used in
this study. Finally, 171 patients with lupus nephritis
were included in this study. This study was approved
by the Institutional Review Board of Severance Hos-
pital, and the need for written informed consent was
waived, as this was a retrospective study (4–2018-
1083).
Evaluation of clinical and laboratory data and
medications
All clinical and laboratory data were assessed at the time
of kidney biopsy. Kidney biopsy was performed in the
patients when the amount of proteinuria was greater
than 1 g per 24 h (either in 24 h urine or spot urine pro-
tein/creatinine (P/Cr) ratio) in the absence of alternative
causes. The demographic data included age, sex and dis-
ease duration after the diagnosis of SLE. The SLE spe-
cific variables included non-renal SLE disease activity
index-2000 (SLEDAI-2 K), complement (C)3, C4, anti-
dsDNA and spot urine P/Cr ratio [13]. Laboratory data
collected were white blood cell count, platelet count,
lymphocyte count, hemoglobin level, erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), creatin-
ine level and albumin level. Investigated clinical
manifestations comprised the components of 1997 ACR
classification criteria, including skin rash, photosensitiv-
ity, oral ulcer, arthritis, serositis and neurologic,
hematologic and immunologic disorder [11]. The num-
ber of patients with hypertension, diabetes mellitus and
dyslipidaemia prior to the diagnosis of lupus nephritis
was counted based on international classification of
diseases-10 and Korean drug utilization review (DUR)
system. For kidney histopathology data, lupus nephritis
class was determined according to the 2003 ISN/RPS
criteria, and the activity and chronicity index were calcu-
lated based on the scoring system from the National
Institutes of Health [3, 14]. Medications that were used
prior and after the diagnosis of lupus nephritis were de-
fined as those for achieving or maintaining the remission
of SLE and were searched by using the Korean DUR sys-
tem. In addition, the adverse effects of glucocorticoid
and immunosuppressive agents and the cumulative dos-
age of glucocorticoid was calculated by using the Hospi-
tal’s electronic medical record system.
Definition of early and delayed lupus nephritis and
clinical outcomes
In this study, early lupus nephritis was defined when
lupus nephritis was histopathologically confirmed as the
first clinical manifestation of SLE, whereas delayed lupus
nephritis was defined as lupus nephritis that was identi-
fied after the diagnosis of SLE. In addition, ESRD was
defined as an impairment of renal function that required
dialysis, while all-cause mortality as death for any reason
during the follow-up. The follow-up duration was deter-
mined as the gap-time from the diagnosis of lupus neph-
ritis to the last visit for the survived patients, to death
for the deceased patients, and to the initiation of dialysis
for the patients with ESRD. Composite outcome was de-
fined as either the presence of ESRD and/or all-cause
mortality.
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Statistical analysis
All statistical analyses were performed using MedCalc
statistical software version 18.11.3 (MedCalc Software,
Ostend, Belgium). Continuous and categorical variables
were represented as median (interquartile ranges) and
frequencies (percentages). Comparison of continuous
variables was performed by Mann-Whitney U test and
categorical variables were compared using chi-square,
chi-square for trend, or the Fisher’s exact test as appro-
priate. Kaplan-Meier analysis with the log-rank test was
used to compare the clinical outcomes of early and de-
layed lupus nephritis. Multivariate Cox-proportional
hazard analysis using statistically significant variables in
univariate analysis was used to evaluate factors
associated with ESRD and all-cause mortality. In all ana-
lysis, a two-tailed p < 0.05 was considered statistically
significant.
Results
Comparison of patient characteristics
The baseline characteristics of patients are shown in
Table 1. The median age was 36.0 years, 153 (89.5%) pa-
tients were women and the median follow-up duration
was 57.1 months. As we divided our patients into early
and delayed lupus nephritis, 106 (62.0%) and 65 (38.0%)
patients were classified as having early and delayed lupus
nephritis. The median disease duration of delayed lupus
nephritis group was 52.6 months, and there was no dif-
ference in the follow-up duration between the groups
after the diagnosis of lupus nephritis was established. Pa-
tients with early nephritis had higher non-renal
SLEDAI-2 K and ESR, but lower anti-dsDNA, WBC
count and albumin levels compared to those with de-
layed lupus nephritis. Regarding clinical manifestations,
patients with early lupus nephritis had a higher inci-
dence of skin rash, oral ulcer and serositis compared to
those with delayed lupus nephritis. In kidney histopath-
ology data, no difference was found in lupus nephritis
classes and activity index, but the proportion of patients
with higher chronicity index was significantly greater in
the delayed lupus nephritis group (p = 0.007). Glucocor-
ticoids were the most frequently selected immunosup-
pressive agents that were used in the delayed lupus
nephritis group prior to the diagnosis of lupus nephritis,
followed by hydroxychloroquine and azathioprine
(Table 2). Medications that were used after the diagnosis
of lupus nephritis were not significantly different be-
tween the groups, except for cyclophosphamide that was
more frequently used in patients with early lupus neph-
ritis than in those with delayed lupus nephritis (39.6%
vs. 23.1%, p = 0.026, Table 3). When we investigated the
adverse effects of glucocorticoid and immunosuppressive
agents, systemic effects were the most common,
followed by infections in both early and delayed lupus
nephritis group. There was no significant difference in
adverse effects between the groups, only except that my-
algia was more common in patients with early lupus
nephritis (Supplementary Table 1).
Comparison of clinical outcomes in patients with early
and delayed lupus nephritis
Kaplan-Meier analysis was carried out to compare the
clinical outcomes in patients with early and delayed
lupus nephritis. No differences in renal and overall sur-
vival rates were found between the groups (log-rank test
p = 0.720 and p = 0.526, Fig. 1a–b). Moreover, the com-
posite outcome free rate was also comparable between
early and delayed lupus nephritis (log-rank test p =
0.335, Fig. 1c).
Predictive factors of the development of ESRD in lupus
nephritis
Among included variables, age, hemoglobin, CRP and
creatinine levels and chronicity index revealed by renal
biopsy were associated with the development of ESRD in
univariate Cox-proportional hazard analysis. Multivariate
analysis revealed that CRP level (odds ratio [OR] 1.021,
95% confidence interval [CI] 1.006–1.037, p = 0.007),
creatinine level (OR 2.233, 95% CI 1.539–3.239, p <
0.001) and chronicity index (OR 1.475, 95% CI 1.042–
2.090, p = 0.029) were predictive factors of ESRD
(Table 4).
Predictive factors associated with all-cause mortality in
lupus nephritis
The univariate Cox-proportional hazard analysis showed
that age and hemoglobin and CRP levels were predictive
of all-cause mortality. However, in multivariate analysis,
only age (OR 1.065, 95% CI 1.018–1.114, p = 0.006) and
hemoglobin level (OR 0.656, 95% CI 0.448–0.959, p =
0.030) were factors that were independently associated
with all-cause mortality during the follow-up (Table 5).
Discussion
The results of this study showed that lupus nephritis af-
fected more than 60% of patients at the time of SLE
diagnosis; however, a substantial number of patients de-
veloped lupus nephritis after SLE was diagnosed. In this
study, the median disease duration of SLE in the delayed
lupus nephritis group was < 5 years, which is consistent
with data of previous studies [8]. Regarding the clinical
characteristics, when lupus nephritis developed early in
the course of SLE, affected patients were more likely to
have higher disease activity and prominent multiple
organ involvement. This finding could be related to the
fact that almost every patient with delayed lupus neph-
ritis was being currently or previously treated with im-
munosuppressive agents. Therefore, it is more likely for
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patients with early lupus nephritis to demonstrate higher
disease activity and systemic inflammation compared to
those with delayed lupus nephritis. However, during the
follow-up period, no difference was found in the clinical
outcomes of the patients, probably due to the similar ef-
fect of administered treatment in these patients.
Therefore, the observations from the current study pro-
vide useful information regarding the management of
patients with lupus nephritis.
An important finding of our study was that the prog-
nosis of patients with early and delayed lupus nephritis
was not significantly different. This fact might be
Table 1 Baseline characteristics of patients with early and delayed lupus nephritis
Variables Total (n = 171) Patients with early lupus
nephritis (n = 106)
Patients with delayed lupus
nephritis (n = 65)
p-value
Demographic data
Age, years 36.0 (26.3–46.0) 36.0 (25.0–48.0) 36.0 (29.0–44.0) 0.903
Female sex, n (%) 153 (89.5) 91 (85.8) 62 (95.4) 0.070
Disease duration, months n/a n/a 52.6 (22.0–118.8) < 0.001
Follow-up duration, months 57.1 (17.5–90.8) 40.9 (14.2–91.3) 67.6 (27.0–88.9) 0.119
SLE specific variables
Non-renal SLEDAI-2 K 5.0 (4.0–7.0) 6.0 (5.0–8.0) 4.0 (4.0–6.0) < 0.001
Complement 3, mg/dL 42.7 (28.7–66.4) 40.3 (26.2–67.3) 46.4 (34.9–64.5) 0.129
Low complement 3, n (%) 154 (90.1) 95 (89.6) 59 (90.8) 0.808
Complement 4, mg/dL 5.6 (3.0–12.5) 5.3 (3.0–12.5) 6.2 (3.5–12.3) 0.623
Low complement 4, n (%) 114 (66.7) 73 (68.9) 41 (63.1) 0.437
Anti-dsDNA (IU/mL) 218.4 (32.3–379.0) 160.0 (10.0–379.0) 300.0 (143.3–379.0) 0.009
Elevated anti-dsDNA, n (%) 141 (82.5) 83 (78.3) 58 (89.2) 0.069
Spot urine P/Cr ratio 2.9 (1.5–6.0) 3.4 (1.5–6.5) 2.3 (1.5–4.2) 0.123
Laboratory data
WBC count (/μL) 4400.0 (3147.5–6145.0) 3925.0 (3030.5630.0) 4950.0 (3947.5–6727.5) 0.018
Platelet count (× 1000/μL) 203.0 (136.3–247.8) 200.0 (113.0–240.0) 213.0 (152.8–253.3) 0.126
Hemoglobin (g/dL) 10.4 (9.1–11.7) 10.2 (8.9–11.5) 10.9 (9.5–11.9) 0.189
Lymphocyte count (/μL) 860.0 (580.0–1227.5) 840.0 (550.0–1250.0) 900.0 (610.-1222.5) 0.999
ESR (mm/hr) 53.0 (28.5–76.0) 57.0 (35.0–84.0) 41.0 (24.8–68.8) 0.013
CRP (mg/L) 2.5 (1.0–8.9) 3.0 (1.0–9.6) 1.9 (1.0–4.9) 0.074
Cr (mg/dL) 0.8 (0.6–1.1) 0.8 (0.6–1.1) 0.8 (0.6–1.0) 0.434
Albumin (g/dL) 2.9 (2.2–3.4) 2.6 (2.1–3.3) 3.2 (2.6–3.4) 0.002
Clinical manifestations
Skin rash 53 (31.0) 41 (38.7) 12 (18.5) 0.006
Photosensitivity 13 (7.6) 10 (9.4) 3 (4.6) 0.374
Oral ulcer 21 (12.3) 19 (17.9) 2 (3.1) 0.004
Arthritis 10 (5.8) 8 (7.5) 2 (3.1) 0.322
Serositis 41 (24.0) 35 (33.0) 6 (9.2) < 0.001
Neurologic disorder 2 (1.2) 1 (0.9) 1 (1.5) 0.726
Hematologic disorder 152 (88.9) 95 (89.6) 57 (87.7) 0.698
Immunologic disorder 159 (93.0) 100 (94.3) 59 (90.8) 0.376
Comorbidities
Hypertension 33 (19.3) 11 (10.4) 22 (33.8) < 0.001
Diabetes mellitus 4 (2.3) 3 (2.8) 1 (1.5) 0.999
Dyslipidemia 2 (1.2) 2 (1.9) 0 (0.0) 0.526
Values are expressed as median (interquartile range) or n (%)
n/a not applicable, SLEDAI-2 K systemic lupus erythematosus disease activity index-2000, P/Cr protein/creatinine, WBC white blood cell, ESR erythrocyte
sedimentation rate, CRP C-reactive protein, Cr creatinine
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Table 2 Comparison of baseline kidney histopathology data and prior immunosuppressive treatment
Variables Total (n = 171) Patients with early lupus
nephritis (n = 106)
Patients with delayed




Class I 3 (1.8) 0 (0.0) 3 (4.6) 0.053
Class IIa 7 (4.1) 4 (3.8) 3 (4.6) 0.999
Class IIIa 57 (33.3) 35 (33.0) 22 (33.8) 0.801
Class IVa 84 (49.1) 53 (50.0) 31 (47.7) 0.770
Class Va 42 (24.6) 29 (27.4) 13 (20.0) 0.279
Class VI 0 (0.0) 0 (0.0) 0 (0.0) 0.999
Activity/Chronicity
Activity index 7.0 (2.0–11.8) 7.0 (2.0–11.0) 8.0 (3.0–12.0) 0.323
Chronicity index, n (%) 0.007
0–1 104 (60.8) 71 (67.0) 33 (50.8)
2–3 51 (29.8) 30 (28.3) 21 (32.3)
4–5 13 (7.6) 4 (3.8) 9 (13.8)
6 3 (1.8) 1 (0.9) 2 (3.1)
Prior immunosuppressive agent use
Glucocorticoids 64 (37.4) 0 (0.0) 64 (98.5) < 0.001
Cyclophosphamide 1 (0.6) 0 (0.0) 1 (1.5) 0.380
Mycophenolate mofetil 2 (1.2) 0 (0.0) 2 (3.1) 0.143
Tacrolimus 1 (0.6) 0 (0.0) 1 (1.5) 0.380
Cyclosporine 2 (1.2) 0 (0.0) 2 (3.1) 0.143
Azathioprine 10 (5.8) 0 (0.0) 10 (15.4) < 0.001
Methotrexate 3 (1.8) 0 (0.0) 3 (4.6) 0.053
Hydroxychloroquine 44 (25.7) 0 (0.0) 44 (67.7) < 0.001
Values are expressed as median (interquartile range) or n (%)
aMixed lupus nephritis cases were counted for each respective class
Table 3 Drugs administered during the follow-up
Variables Total (n = 171) Patients with early lupus
nephritis (n = 106)
Patients with delayed
lupus nephritis (n = 65)
p-value
Immunosuppressive agents
Glucocorticoids 171 (100.0) 106 (100.0) 65 (100.0) 0.999
Cumulative glucocorticoid dosage (mg)a 11,315.0 (5195.3–18,697.5) 10,889.6 (5145.0–17,306.3) 14,370.0 (5472.5–20,703.8) 0.181
Cyclophosphamide 57 (33.3) 42 (39.6) 15 (23.1) 0.026
Mycophenolate mofetil 133 (77.8) 83 (78.3) 50 (76.9) 0.834
Tacrolimus 37 (21.6) 24 (22.6) 13 (20.0) 0.685
Cyclosporine 8 (4.7) 6 (5.7) 2 (3.1) 0.711
Azathioprine 24 (14.0) 13 (12.3) 11 (16.9) 0.396
Hydroxychloroquine 98 (57.3) 55 (51.9) 43 (66.2) 0.051
Values are expressed as median (interquartile range) or n (%)
aCumulative glucocorticoid dosage was calculated in prednisolone equivalent dosage
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explained by several reasons. First, because current ACR
guidelines recommend kidney biopsy for patients with
SLE to assess the possibility of lupus nephritis when pro-
teinuria exceeds 1 g [4], the timely intervention to diag-
nose lupus nephritis and manage inflammation might
have hampered the development of irreversible organ
damage and in affecting patient mortality. Thus, our
findings further emphasize that strict adherence to the
current practice guidelines is essential for the proper
management of SLE. Second, only a few patients with
delayed lupus nephritis were previously treated with
cyclophosphamide and mycophenolate mofetil, which is
the most commonly used immunosuppressive agent to
induce remission in lupus nephritis [15]. Therefore,
while almost every patient with delayed lupus nephritis
were on immunosuppression, the prior treatment might
not have been sufficient to prevent the development of
lupus nephritis and influence the treatment response of
Fig. 1 Kaplan-Meier curve analysis of clinical outcomes in patients with early and delayed lupus nephritis. The clinical outcomes of renal survival
rate (a), overall survival rate (b), and composite outcome free rate (c) was compared in patients with early and delayed lupus nephritis
Table 4 Univariate and multivariate Cox-proportional hazard analysis of variables associated with end-stage renal disease
Univariate analysis Multivariate analysis
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Age, years 1.046 1.007–1.086 0.021
Female sex 1.648 0.215–12.638 0.631
SLEDAI-2 K 0.915 0.791–1.057 0.227
Complement 3, mg/dL 0.989 0.967–1.011 0.327
Complement 4, mg/dL 0.971 0.897–1.051 0.470
Anti-dsDNA (IU/mL) 0.998 0.995–1.001 0.183
Spot urine P/Cr ratio 1.001 0.863–1.159 0.995
WBC count (/μL) 1.000 0.999–1.000 0.900
Platelet count (×1000/μL) 0.995 0.989–1.002 0.139
Hemoglobin (g/dL) 0.601 0.455–0.795 < 0.001
Lymphocyte count (/μL) 0.999 0.998–1.000 0.099
ESR (mm/hr) 1.006 0.990–1.022 0.493
CRP (mg/L) 1.015 1.002–1.028 0.028 1.021 1.006–1.037 0.007
Cr (mg/dL) 2.445 1.801–3.317 < 0.001 2.233 1.539–3.239 < 0.001
Albumin (g/dL) 0.620 0.306–1.259 0.186
Activity index 1.058 0.959–1.167 0.261
Chronicity index 1.581 1.199–2.083 0.001 1.475 1.042–2.090 0.029
Early lupus nephritis 0.830 0.295–2.337 0.725
Delayed lupus nephritis 1.204 0.428–3.388 0.725
SLEDAI-2 K systemic lupus erythematosus disease activity index-2000, P/Cr protein/creatinine, WBC white blood cell, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, Cr creatinine
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induction and maintenance therapies. Conversely, al-
though patients with early lupus nephritis exhibited
higher disease activity, and thus, were more likely to be
treated with cyclophosphamide, the application of ag-
gressive treatment with cyclophosphamide might have
resulted in similar clinical outcomes in early and delayed
lupus nephritis.
Notably, a recent publication by Ugolini-Lopes and
colleagues have evaluated the clinical outcomes in pa-
tients with early-onset and late-onset lupus nephritis
and found a similar prognosis in both groups [10]. In
their study, early-onset lupus nephritis was defined as
lupus nephritis occurring in the first 5 years of SLE diag-
nosis and late-onset lupus nephritis as that occurring
after 5 years of disease diagnosis. Similar findings were
also found regarding the clinical outcomes in this study,
and the renal and overall survival rate of early and de-
layed lupus nephritis was not significantly different in
Kaplan-Meier curve analysis. Although different defini-
tions were adopted for early and delayed lupus nephritis,
the present study has several advantages compared to
the study by Ugolini-Lopes et al. in terms of a larger
number of patients with Asian ethnicity, evaluated fac-
tors associated with ESRD and all-cause mortality and
detailed data regarding immunosuppressive agents used
before and after the diagnosis of lupus nephritis.
Even though the advances of lupus nephritis treatment
have led to a lower occurrence of ESRD in the recent de-
cades [16], ESRD still remains to be one of the most
morbid condition in lupus nephritis [17]. In multivariate
Cox-proportional hazard analysis, higher creatinine and
CRP levels along with higher chronicity index at baseline
were found to be predictive factors for ESRD. Consist-
ently, poor renal function at initial presentation and
higher chronicity index were shown to be predictors of
ESRD progression in patients with lupus nephritis [18].
An interesting finding of this study was that even though
patients with delayed lupus nephritis had a greater pro-
portion of patients with higher chronicity index, the
renal outcome was not significantly different compared
to those of patients with early lupus nephritis. This
could be related to the fact that the difference in the
Table 5 Univariate and multivariate Cox-proportional hazard analysis of variables associated with all-cause mortality
Univariate analysis Multivariate analysis
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Age, years 1.066 1.019–1.115 0.006 1.065 1.018–1.114 0.006
Female sex 1.117 0.141–8.851 0.917
SLEDAI-2 K 0.927 0.782–1.099 0.382
Complement 3, mg/dL 0.990 0.963–1.017 0.443
Complement 4, mg/dL 0.924 0.814–1.048 0.220
Anti-dsDNA (IU/mL) 0.998 0.995–1.002 0.314
Spot urine P/Cr ratio 0.682 0.458–1.017 0.060
WBC count (/μL) 1.000 0.999–1.000 0.445
Platelet count (×1000/μL) 1.000 0.993–1.007 0.996
Hemoglobin (g/dL) 0.653 0.467–0.913 0.013 0.656 0.448–0.959 0.030
Lymphocyte count (/μL) 0.999 0.998–1.001 0.361
ESR (mm/hr) 1.010 0.991–1.029 0.323
CRP (mg/L) 1.017 1.001–1.033 0.034
Cr (mg/dL) 1.479 0.889–2.461 0.132
Albumin (g/dL) 0.927 0.399–2.152 0.860
Activity index 1.004 0.892–1.129 0.954
Chronicity index 1.233 0.861–1.766 0.252
Early lupus nephritis 0.671 0.194–2.319 0.529
Delayed lupus nephritis 1.490 0.431–5.148 0.529
Hypertension 2.965 0.834–10.539 0.093
Diabetes mellitusa n/a
Dyslipidemiaa n/a
SLEDAI-2 K systemic lupus erythematosus disease activity index-2000, P/Cr protein/creatinine, WBC white blood cell, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, Cr creatinine, n/a not applicable
aThe odds ratio was not calculable because no death occurred in patients with diabetes mellitus and dyslipidaemia
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chronicity index between the groups was not large
enough to reach statistical significance. Therefore, this
finding should be verified in future studies.
It has been reported that lupus nephritis is associated
with significantly higher mortality in SLE [19]. When we
evaluated factors associated with higher mortality, age
was associated with increased risk of mortality, while
higher hemoglobin level was associated with lower risk
of mortality independently of traditional risk factors,
such as of hypertension, diabetes mellitus and dyslipi-
daemia [20–22]. Old age is closely linked to increased
risk of mortality in the general population [23]. How-
ever, the association with mortality in lupus nephritis is
controversial. A previous study has demonstrated that
age was a predictor of death in patients with lupus neph-
ritis [24], while in a recent publication by Teh et al. age
was not associated with the risk of mortality [25]. These
discrepant results between the studies may be related to
the different ethnic groups included and the selection of
variables for the analysis. On the other hand, anemia
was also reported to be an independent factor related to
mortality in patients with chronic inflammatory diseases
and malignancies [26–28]. Although the direct associ-
ation between anemia and higher mortality in lupus
nephritis is unclear, it could be indirectly associated with
higher inflammation in lupus nephritis based on the fact
that hemoglobin level could decrease in association with
inflammatory burden or as a consequence of impaired
renal function [29, 30]. Overall, it could be suggested
that age and hemoglobin level should be taken into ac-
count when predicting mortality among patients with
lupus nephritis.
The main strengths of the present study were the large
number of included patients with Asian ethnicity and
pathologically confirmed lupus nephritis for the evaluation
of outcomes. However, it also has several inherent limita-
tions. First, patient data and adverse effects of glucocortic-
oid and immunosuppressive agents were investigated
retrospectively by reviewing the medical records. Second,
the follow-up period of the included patients was relatively
short. Third, we were not able to precisely assess the effect
of used immunosuppressive agents on the patient progno-
sis. Fourth, the application of 1997 revised ACR classifica-
tion criteria, which possess lower sensitivity as compared
to the 2012 SLE International Collaborating Clinics cri-
teria and the 2019 European League Again Rheumatism/
ACR criteria, could have resulted in selection or classifica-
tion bias. Additional investigations are necessary to com-
paratively assess clinical outcomes of early and delayed
lupus nephritis.
Conclusions
In conclusion, the distinct clinical features of early lupus
nephritis are higher disease activity and more frequent
multiple organ involvement. However, long-term clinical
outcomes of early and delayed lupus nephritis appear to
be similar. Rigorous adherence to current treatment rec-
ommendations is important in providing optimal treat-
ment for patients with lupus nephritis.
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